Literature DB >> 15379656

The central role of angiotensin I-converting enzyme in vertebrate pathophysiology.

David W Moskowitz1, Frank E Johnson.   

Abstract

Genomic epidemiologic data, increasingly supported by clinical outcomes results, strongly suggest that overactivity of angiotensin I-converting enzyme (ACE) may underlie most age-related diseases. Angiotensin II, the main product of ACE, is a pleiotropic hormone, capable of serving as a neurotransmitter, growth factor, angiogenesis factor, vasoconstrictor, pro-thrombotic agent, and cytokine. So it is perhaps not surprising that the ACE D/D genotype is associated with several major psychiatric diseases, most cancers except prostate cancer (where the D/D genotype is actually protective), most cardiovascular diseases, most autoimmune diseases, and even infectious diseases like tuberculosis and HIV. In a preliminary study, angiotensin II blockade appeared to hasten recovery from West Nile virus encephalitis; it may be equally useful in SARS. The ACE gene underwent duplication at the origin of Chordata, just before the "Cambrian Explosion" in the number of species. The ancestral, unduplicated form of ACE is still expressed during the terminal differentiation of human spermatocytes, suggesting a critical role in reproduction. The crystal structure of testicular ACE (tACE) was recently published. Computer modeling suggests that tACE may be activated by both mechanical forces and reducing agents. The duplicated form of ACE (somatic ACE, sACE) is expressed in areas of high fluid flow. sACE may auto-dimerize via a novel protein motif, the "disulfide zipper." The sACE dimer is predicted to have higher catalytic efficiency and redox resistance than tACE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379656     DOI: 10.2174/1568026043387818

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  10 in total

1.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.

Authors:  Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Journal:  Cell Discov       Date:  2020-03-16       Impact factor: 10.849

2.  Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer.

Authors:  Hiroji Uemura; Hisashi Hasumi; Takashi Kawahara; Shinpei Sugiura; Yasuhide Miyoshi; Noboru Nakaigawa; Jun-ichi Teranishi; Kazumi Noguchi; Hitoshi Ishiguro; Yoshinobu Kubota
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.402

3.  Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study.

Authors:  Jesper Hallas; Rene Christensen; Morten Andersen; Søren Friis; Lars Bjerrum
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

4.  Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California.

Authors:  Samuel J S Rubin; Samuel R Falkson; Nicholas R Degner; Catherine A Blish
Journal:  J Clin Transl Sci       Date:  2021-06-01

5.  Critical symbiont signals drive both local and systemic changes in diel and developmental host gene expression.

Authors:  Silvia Moriano-Gutierrez; Eric J Koch; Hailey Bussan; Kymberleigh Romano; Mahdi Belcaid; Federico E Rey; Edward G Ruby; Margaret J McFall-Ngai
Journal:  Proc Natl Acad Sci U S A       Date:  2019-03-04       Impact factor: 11.205

6.  The prevention of pain from sickle cell disease by trandolapril.

Authors:  R Michael Williams; David W Moskowitz
Journal:  J Natl Med Assoc       Date:  2007-03       Impact factor: 1.798

7.  National common metrics for the NIH Clinical and Translational Science Award Institutions: A signal of the transformation of the American biomedical research enterprise.

Authors:  Harry P Selker
Journal:  J Clin Transl Sci       Date:  2019-10-08

8.  Design, Synthesis, and Study of a Novel RXPA380-Proline Hybrid (RXPA380-P) as an Antihypertensive Agent.

Authors:  Moaz M Abdou; Dewen Dong; Paul M O'Neill; Eric Amigues; Magdalini Matziari
Journal:  ACS Omega       Date:  2022-09-23

9.  Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.

Authors:  Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Journal:  Cell Discov       Date:  2020-03-16       Impact factor: 10.849

Review 10.  A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.

Authors:  Zemene Demelash Kifle; Engidaw Fentahun Enyew; Abebe Basazn Mekuria
Journal:  J Evid Based Integr Med       Date:  2021 Jan-Dec
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.